Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases experience from a national registry (GRAID) 英文参考文献.docVIP

下载本文档

5
0
约6.21万字
约 14页
2017-05-13 发布于上海
举报
版权申诉

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases experience from a national registry (GRAID) 英文参考文献.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases experience from a national registry (GRAID) 英文参考文献

Tonyetal.ArthritisResearchTherapy2011,13:R75 /content/13/3/R75 RESEARCH ARTICLE OpenAccess Safetyandclinicaloutcomesofrituximabtherapy inpatientswithdifferentautoimmunediseases: experiencefromanationalregistry(GRAID) Hans-PeterTony1,GerdBurmester2,HendrikSchulze-Koops3,MathiasGrunke3,JoergHenes4,InaK?tter4, JudithHaas5,LeonoreUnger6,SvjetlanaLovric7,MarionHaubitz7,RebeccaFischer-Betz8,GamalChehab8, AndreaRubbert-Roth9,ChristofSpecker10,JuttaWeinerth11,JuliaHolle12,UlfMüller-Ladner13,RamonaK?nig13, ChristophFiehn14,PhilipBurgwinkel2,KlemensBudde2,HelmutS?rensen15,MichaelMeurer16,MartinAringer16, BerndKieseier8,CorneliaErfurt-Berge17,MichaelSticherling17,RolandVeelken17,UlfZiemann18,FrankStrutz19, PraxisvonWussow20,FlorianMPMeier21,NicoHunzelmann22,EnnoSchmidt23,RaoulBergner24, AndreasSchwarting25,RüdigerEming26,MichaelHertl26,RudolfStadler27,MichaelSchwarz-Eywill28, SiegfriedWassenberg29,MartinFleck30,ClaudiaMetzler31,UweZettl32,JensWestphal33,StefanHeitmann34, AnnaLHerzog35,HeinzWiendl35,WaltraudJakob36,ElviraSchmidt36,KlausFreivogel36,ThomasD?rner2* and GRAIDinvestigators Abstract Introduction:Evidencefromanumberofopen-label,uncontrolledstudieshassuggestedthatrituximabmay benefitpatientswithautoimmunediseaseswhoarerefractorytostandard-of-care.Theobjectiveofthisstudy wastoevaluatethesafetyandclinicaloutcomesofrituximabinseveralstandard-of-care-refractoryautoimmune diseases(withinrheumatology,nephrology,dermatologyandneurology)otherthanrheumatoidarthritisor non-Hodgkin’slymphomainareal-lifeclinicalsetting. Methods:Patientswhoreceivedrituximabhavingshownaninadequateresponsetostandard-of-carehadtheir safetyandclinicaloutcomesdataretrospectivelyanalysedaspartoftheGermanRegistryofAutoimmuneDiseases. Themainoutcomemeasuresweresafetyandclinicalresponse,asjudgedatthediscretionoftheinvestigators. Results:Atotalof370patients(299patient-years)withvariousautoimmunediseases(23.0%withsystemiclupus erythematosus,15.7%antineutrophilcytoplasmicantibody-associatedgranulomato